Crinetics Pharmaceuticals (NASDAQ: CRNX): Investor Relations Program

Crinetics Pharmaceuticals (NASDAQ: CRNX) is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Founded in 2008, Crinetics has garnered attention for its innovative approach to addressing unmet medical needs in endocrinology. LifeSci engaged in September 2020 to manage the investor relations strategy for Crinetics.


  • Transparency and Communication: LifeSci helped Crinetics to determine appropriate expectations, craft messaging around those expectations, and carry through with them.
  • Investor Education: LifeSci helped create a clear investor targeting strategy that optimized the management team’s time and resources. The strategy required selectivity and prioritization to avoid fatigue, as apposed to adopting an “any and all” approach.
  • Consistency was Critical: Through various channels such as presentations, calls, and conferences, Crinetics successfully educated investors on their innovative pipeline, emphasizing their recent positive initial findings for their Phase 2 Data on their oral, once-daily investigational compound.
  • Analyst Relationships: Crinetics has 13 covering analysts. With LifeSci’s support, the company strategically managed these relationships with careful consideration and guidance, fostering a critical yet supportive analyst base.

Priced at $42.00 per share, Crinetics announced an oversubscribed $350 Million private placement. Following their PIPE deal, Crinetics’s Market Cap has since tripled in size and is now sitting at $3.5 Billion.